EUVIMEDEUVIMED entdecken
Open Access

Circulating-tumor DNA Assessment in Diffuse Large B-cell Lymphoma to Determine Up-front Stem Cell Transplantation: A Pilot Study

Juhyung Kim, Tan Minh LE, Donghyeon Lee, Hong Duc Thi Nguyen, Hee Jeong Cho, Sang Kyun Sohn, Jong Gwang Kim, Shin-Young Jeong, Ji Yeon Ham, Ji Yun Jeong, Hyung Soo Han, Joon Ho Moon und 1 weitere

In Vivo · 2024

DOI: 10.21873/invivo.13448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Juhyung Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: This study evaluated the possibility of clinical use of circulating-tumor DNA (ctDNA) as a biomarker to determine up-front autologous stem cell transplantation (auto-SCT) for patients with high-risk diffuse large B-cell lymphoma (DLBCL) in practice. PATIENTS AND METHODS: To explore the dynamics of ctDNA in DLBCL, blood samples were collected sequentially before and after treatment from patients with newly diagnosed DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. To conduct ctDNA genotyping and ctDNA monitoring simultaneously, targeted sequencing by cancer personalized profiling using deep sequencing was used. RESULTS: Ten patients between the ages of 50 and 60 years were enrolled. Based on the international prognostic index (IPI), seven patients were classified as high-IPI-risk group, and three patients were classified as low-IPI-risk group. The IPI risk group correlated with total metabolic tumor volume. All patients completed six cycles of R-CHOP chemotherapy, and seven patients achieved complete response. Changes in ctDNA mutation numbers did not correlate with changes in PET scan images and treatment response. In most high-risk patients, new mutations appeared in ctDNA after completion of chemotherapy that conceivably marked resistant clones. Notably, disease relapse did not occur in high-risk patients with poor prognostic mutations who underwent autologous SCT. CONCLUSION: ctDNA monitoring was meaningful in high-risk patients. Moreover, ctDNA and well-known prognostic factors should be considered in the decision making for auto-SCT. If a new genetic mutation in ctDNA with a negative prognosis would emerge during treatment, high-risk patients should consider auto-SCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseHumansMiddle AgedPilot ProjectsNeoplasm Recurrence, LocalTransplantation, AutologousStem Cell TransplantationPrognosisCyclophosphamidePrednisoneAntineoplastic Combined Chemotherapy ProtocolsDoxorubicinVincristineDNA

Stichwörter der Autor:innen

Circulating-tumor DNAdiffuse large B-cell lymphomastem cell transplantationsurvival

Substanzen

CyclophosphamidePrednisoneDoxorubicinVincristineDNA

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Biomedical Science, Graduate School, Kyungpook National University, Daegu, Republic of Korea.
  • BK21 Four Program, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Laboratory Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Pathology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

Zitieren

APA

Kim, J., LE, T. M., Lee, D., Nguyen, H. D. T., Cho, H. J., Sohn, S. K., Kim, J. G., Jeong, S. Y., Ham, J. Y., Jeong, J. Y., Han, H. S., Moon, J. H., & Baek, D. W. (2024). Circulating-tumor DNA Assessment in Diffuse Large B-cell Lymphoma to Determine Up-front Stem Cell Transplantation: A Pilot Study. In Vivo. https://doi.org/10.21873/invivo.13448

Vancouver

Kim J, LE TM, Lee D, Nguyen HDT, Cho HJ, Sohn SK, et al. Circulating-tumor DNA Assessment in Diffuse Large B-cell Lymphoma to Determine Up-front Stem Cell Transplantation: A Pilot Study. In Vivo. 2024. doi:10.21873/invivo.13448

BibTeX
@article{Kim2024,
  author = {Kim, Juhyung and LE, Tan Minh and Lee, Donghyeon and Nguyen, Hong Duc Thi and Cho, Hee Jeong and Sohn, Sang Kyun and Kim, Jong Gwang and Jeong, Shin-Young and Ham, Ji Yeon and Jeong, Ji Yun and Han, Hyung Soo and Moon, Joon Ho and Baek, Dong Won},
  title = {Circulating-tumor DNA Assessment in Diffuse Large B-cell Lymphoma to Determine Up-front Stem Cell Transplantation: A Pilot Study},
  journal = {In Vivo},
  year = {2024},
  doi = {10.21873/invivo.13448}
}
Kostenlos starten →